Browse all 651 ETFs by category, no search needed
Global 184
US market 62
Country 92
Core UCITS 16
Sector 103
Style & factor 112
Theme 45
Dividend 37
SPDR® S&P Biotech ETF (XBI)
Look-through valuation · Sector · Expense ratio 0.35 % · ISIN US78464A8707
Price history (since 2006)
Monthly close since 2006. Price shows performance, the valuation verdict is in the look-through above.
Top holdings
| Holding | Weight | vs fair value | Quality |
|---|---|---|---|
| Moderna Inc MRNA | 2.8 % | n/a | n/a |
| Twist Bioscience Corp TWST | 2.0 % | n/a | n/a |
| Apogee Therapeutics, Inc. Common Stock APGE | 1.4 % | n/a | n/a |
| Natera Inc NTRA | 1.4 % | −95.1 % | 37 |
| Kymera Therapeutics Inc KYMR | 1.4 % | n/a | n/a |
| Revolution Medicines Inc RVMD | 1.4 % | n/a | n/a |
| Praxis Precision Medicines Inc PRAX | 1.4 % | n/a | n/a |
| Halozyme Therapeutics Inc HALO | 1.3 % | −44.2 % | 79 |
| Oruka Therapeutics, Inc. ORKA | 1.3 % | n/a | n/a |
| Dianthus Therapeutics Inc. DNTH | 1.3 % | n/a | n/a |
| Erasca Inc ERAS | 1.3 % | n/a | n/a |
| Travere Therapeutics Inc TVTX | 1.3 % | −96.4 % | 35 |
| CG Oncology, Inc. Common stock CGON | 1.3 % | n/a | n/a |
| Protagonist Therapeutics Inc PTGX | 1.3 % | −97.7 % | 39 |
| Vaxcyte Inc PCVX | 1.2 % | n/a | n/a |
| Scholar Rock Holding Corp SRRK | 1.2 % | n/a | n/a |
| Regeneron Pharmaceuticals Inc REGN | 1.2 % | −25.2 % | 72 |
| Roivant Sciences Ltd ROIV | 1.2 % | n/a | n/a |
| Sellas Life Sciences Group Inc SLS | 1.2 % | n/a | n/a |
| Insmed Inc INSM | 1.2 % | n/a | n/a |
| Rhythm Pharmaceuticals Inc RYTM | 1.2 % | n/a | n/a |
| Amgen Inc AMGN | 1.2 % | −41.7 % | 63 |
| Vertex Pharmaceuticals Inc VRTX | 1.1 % | −48.5 % | 79 |
| Arrowhead Pharmaceuticals Inc ARWR | 1.1 % | −89.1 % | 51 |
| Spyre Therapeutics Inc. SYRE | 1.1 % | n/a | n/a |
Fair value and quality per position come from the same valuation as our stock pages. Showing the 25 largest of 50 disclosed positions. "n/a" means the position is not (yet) in our stock universe and does not enter the average.
The 10 most cheaply valued ETFs
Measured against the look-through fair value of the holdings (sufficiently covered funds only). Green means below fair value, red above. Not financial advice.
- 1 CHIU Global X MSCI China Utilities ETF +65.3 % below FV
- 2 FXI iShares China Large-Cap ETF +52.1 % below FV
- 3 CHIQ Global X MSCI China Consumer Disc ETF +50.4 % below FV
- 4 KWEB KraneShares CSI China Internet ETF +39.3 % below FV
- 5 FLCH Franklin FTSE China ETF +34.7 % below FV
- 6 FCFY First Trust S&P 500 Diversified Free Cash Flow ETF +30.7 % below FV
- 7 MCHI iShares MSCI China ETF +26.5 % below FV
- 8 TAN Invesco Solar ETF +14.6 % below FV
- 9 ITB iShares U.S. Home Construction ETF +12.9 % below FV
- 10 C003 Amundi Index Solutions - Amundi DivDAX I UCITS ETF EUR Distributing +7.8 % below FV
How we value this ETF
An ETF has no fair value of its own like a single stock. We build it bottom up: every holding has a fair value and a quality score on our pages. Weighted by portfolio share, that gives SPDR® S&P Biotech ETF an average of how cheap or expensive its companies currently sit versus fair value, and how high their average quality is.
As of: Aug 31, 2026
The look-through is a computed summary of public fundamentals and is no substitute for your own research.